Aligos Therapeutics reported a net loss of $82.2 million for the fourth quarter of 2024, compared to a net loss of $27.9 million for the same period in 2023. The net loss for the full year 2024 was $131.2 million, an increase from $87.7 million in 2023. This increase was largely driven by a $60.8 million loss from the change in fair value of common warrants in Q4 2024.
Research and development (R&D) expenses for Q4 2024 decreased to $16.0 million from $22.3 million in Q4 2023, primarily due to reduced third-party clinical trial expenses. For the full year 2024, R&D expenses were $70.3 million, a decrease from $73.0 million in 2023. General and administrative (G&A) expenses also decreased for both the quarter and full year.
As of December 31, 2024, cash, cash equivalents, and investments totaled $56.9 million. However, inclusive of the $105 million private placement completed on February 13, 2025, the company expects its cash runway to extend into the second half of 2026. The company anticipates the Phase 2 clinical study for ALG-000184 to begin in mid-2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.